How large are the differences between originator and generic prices? Analysis of five molecules in 16 European countries

Sabine Vogler 1

1 Head of Pharma Team, Head of WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Wien, Austria

INTRODUCTION

A generic medicine is a pharmaceutical product which has the same qualitative and quantitative composition in active substances and the same pharmaceutical form as the reference original medicine, and whose bioequivalence with the reference medicine has been demonstrated by appropriate bioavailability studies [1]. Generics are launched when the patent of the originator product has expired. Whereas the quality of generics is with no difference to the one of original products, they tend to be cheaper: the European Generics Medicines Association indicates generic prices being 20 to 90 percent lower than those of original medicines [2].

Therefore, generics are seen as a major policy option for cost-containment since, due to their lower prices, they benefit the health care systems by providing savings which might be used for funding innovation. An international study covering 17 countries worldwide found out that cost savings of more than 50 percent could be generated in all but two of 17 studied countries surveyed if consumption shifted from the originator brand product to the lowest-priced generic equivalent available at medicine outlets in the private sector [3].

ABSTRACT

OBJECTIVE: To survey the price differences between originators and generics for a selected basket of molecules and to analyze similarities and differences with regard to the countries included and their generic policies. METHODS: Ex-factory prices as of November 2011 of five molecules provided from the Pharma Price Information (PPI) service of the Austrian Health Institute were analyzed for 16 European countries (Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, the Netherlands, Norway, Portugal, Spain, Switzerland, Sweden, UK). The selected molecules were gemcitabine, mycophenolate mofetil, olanzapine, risperidone and sumatriptan. For a specific presentation (same pack size, dosage and pharmaceutical form) of each molecule, the prices of the original product and the “most common generic” as defined by PPI were compared. RESULTS: Considerable variations among the extent of price differences between originator and generic were identified (gemcitabine: lowest price difference of 1.4% between originator and generic in Belgium and highest difference of 73.4% in Portugal; mycophenolate mofetil: 3.4% Norway – 71.7% Netherlands; olanzapine: 0.1% Spain – 97.1% Sweden; risperidone: 0.9% Netherlands – 97.3% UK; sumatriptan: 5.8% Greece – 95.0% Denmark). Further, no difference at all between originator and generic prices was found for some molecules in a few countries (Norway: for 4 of the 5 molecules analyzed; Spain: 3; Belgium: 2; in Austria, France and Greece for one molecule respectively). For the five molecules of the sample, Greece, Spain, Ireland and Norway consistently displayed lower price differences whereas Denmark, Finland and Sweden tended to show higher differences between originator and generic prices. CONCLUSION: Even if this research is illustrative and not representative due to the small sample size, results suggest confirming large differences across Europe. It appears that countries (e.g. Denmark, Sweden) with strong generic policies, particularly based on competition and involving elements of enforcement, tend to have higher differences between originator and generic prices. Further research, notably with a broader basket, is recommended.

Keywords
Generic policies; Medicines prices; Pricing; Price difference; Europe; Competition; Regulation
How large are the differences between originator and generic prices? Analysis of five molecules in 16 European countries

METHODS

A basket of five molecules whose patent had already expired was selected for the analysis. The selected medicines are applied in different indications. Included in the analysis were: gemcitabine (an anti-neoplastic agent), mycophenolate mofetil (immunosuppressant), olanzapine (anti-depressant), risperidone (anti-psychotic) and sumatriptan (analogetic).

The price survey and analysis was undertaken for 16 European countries, some of them being major pharmaceutical markets: Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, the Netherlands, Norway, Portugal, Spain, Switzerland, Sweden, and the UK.

Data were provided by the Pharma Price Information (PPI) service of the Austrian Health Institute [24]. The PPI service is an information service which offers medicine prices of the EU Member States covering all price types. It was established to support, according the Austrian General Social Insurance Law [25], the Austrian Pricing Committee located at the Austrian Federal Ministry of Health which calculates the EU average price which is needed for price setting since Austria applies external price referencing and sets its prices based on the average prices of the prices in all other EU Member States [26]. Data of the PPI service are provided to the Austrian Pricing Committee on a yearly basis (18 of the European Union Member States); only one EU Member State (Austria) implemented none of these three measures [15]. At the supply side, the “generic price link,” i.e. setting the price of a generic medicine at a specific rate below the originator price, is also a common feature in shaping generic policies [9,13,15]. In current economically difficult times, generic policies are considered as a policy option to further develop even though they are not – such as price reductions and co-payments – the top emergency measures in response to the global financial crisis [16].

Generic medicines prices have been surveyed and analyzed in international price comparisons, both at global and European level [17-21]. The extent of the differences between the prices of generics and original medicines was surveyed in fewer studies. One important report in this respect is the Pharmaceutical Sector Inquiry 2009 of the European Commission: it showed that in 17 EU Member States generics enter the market at on average a price slightly under 80% of the originator’s price. After three years the prices of both the originator and the generics dropped on average to about 75% and 55% respectively of the originator’s price at generic entry [22]. The study design of the Pharmaceutical Sector Inquiry, an analysis of relative prices, was challenged, and concern was expressed that the reasons for the variability and the potential role and interplay of regulation and competition were not sufficiently investigated [23]. This study particularly aims to survey the extent of the price differences between generic and original medicines and compare them across European countries. Price differences for a basket of selected molecules among European countries are analyzed, and a possible relationship to the generic prices, generics market shares and generic policies will be explored.
at request to all interested parties and might also be requested for research.

Prices were analyzed at the ex-factory price level, since the issue of distribution margins was not scope of this study. Data were provided as of November 2011. Price data from non-Euro countries were converted into Euro based on the monthly exchange rate of the European Central Bank as of November 2011. A pair of a specific original product and an identical generic was subject to the analysis, thus comparing presentations in the same pack size, dosage and pharmaceutical form. In determining the identical presentation the author was guided by the Defined Daily Dose (DDD) as stipulated by the WHO Collaborating Centre for Drug Statistics Methodology in Oslo, and checked a larger PPI data set to identify pairs of originator and generic medicines available in several countries.

For some of the selected presentations, generics from more than one supplier were offered – sometimes, but not always – with the same price. Included into the analysis were those generics which the PPI service had defined as the “most common generic”. Suppliers of the most common generic might differ among the countries.

Prices and price differences were analyzed at unit price level. The prices were calculated per DDD because for the given research question a unit price analysis served better the purpose to understand pricing strategies. Furthermore, two of the molecules selected had no DDD allocated due to their highly individualized use, and applying country specific DDDs would have distorted the analysis.

In some cases data on the original product and the corresponding generic in the defined presentation were not available because products, usually the generic versions, were not marketed in these pack sizes, dosages and/or pharmaceutical forms. In order to achieve high data coverage, the following exemptions for the pairs analyzed were accepted: different but similar pack sizes (e.g. 30 units instead of 28 units) were included in the analysis. Deviations to the pharmaceutical form were rarely permitted, only in the case of film-coated tablets, tablets and capsules. Similar strengths (e.g. 6 mg instead of 4 mg) were accepted in very few cases. While these variiances were allowed among the countries analyzed, the pair of an original product and its comparable generic per country needed to have the identical pack size, dosage and pharmaceutical form (one exemption: olanzapine, the Netherlands). Despite these exemptions data had to be excluded in some countries because no generic corresponding to the originator was on the market.

Table I provides an overview about the five analyzed molecules including methodologi-

<table>
<thead>
<tr>
<th>Molecule</th>
<th>Indication</th>
<th>Defined daily dose (DDD)*</th>
<th>Selected presentation</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gemcitabine</td>
<td>Breast cancer, anti-neoplastic agent</td>
<td>No DDD defined</td>
<td>1 vial containing 1 g powder for solution for infusion</td>
<td>Comparable data available for 12 countries. No price comparison possible in DE, ES, IE, SE due to missing generics in a comparable presentation</td>
</tr>
<tr>
<td>Mycophenolate mofetil</td>
<td>Immunosuppressant</td>
<td>No DDD defined</td>
<td>100 caps 250 mg</td>
<td>Comparable data available for 16 countries. AT: different pack size and dosage (150 500 mg f/c tabs), BE, CH, DK: 300 units, but same dosage and pharmaceutical form</td>
</tr>
<tr>
<td>Olanzapine</td>
<td>Schizophrenia, anti-depressant</td>
<td>10 mg</td>
<td>28 f/c tabs 10 mg</td>
<td>Comparable data available for 13 countries. No price comparison possible in CH, DE, DK due to missing generics in a comparable presentation. NL: data adjusted at unit level – 30 units/pack for original product, 28 units/pack for generic. NO: different pharmaceutical form: orodispersible tabs, SE: 56 units, same dosage and pharmaceutical form</td>
</tr>
<tr>
<td>Risperidone</td>
<td>Schizophrenia, anti-psychotic</td>
<td>5 mg</td>
<td>60 f/c tabs 4 mg</td>
<td>Comparable data available for 16 countries</td>
</tr>
<tr>
<td>Sumatriptan</td>
<td>Migraine, analgetic, SS antagonist</td>
<td>50 mg (oral)</td>
<td>6 f/c tabs 50 g</td>
<td>Comparable data available for 11 countries. No price comparison possible in AT, FI, FR, IT, SE due to missing generics in a comparable presentation ES and EL: 4 units, PT: 2 units, same pack size and pharmaceutical form; BE: 100 mg f/c tabs</td>
</tr>
</tbody>
</table>

Table I. Molecules analyzed and limitations regarding comparability* as defined by the WHO Collaborating Centre for Drug Statistics Methodology, Oslo [27]

AT = Austria; BE = Belgium; CH = Switzerland; DE = Germany; DK = Denmark; EL = Greece; ES = Spain; FI = Finland; IE = Ireland; IT = Italy; NO = Norway; SE = Sweden

Farmeconomia. Health economics and therapeutic pathways 2012; 13(Suppl 3) © SEEd All rights reserved
How large are the differences between originator and generic prices? Analysis of five molecules in 16 European countries

How large are the differences between originator and generic prices? Analysis of five molecules in 16 European countries

mycophenolate mofetil: 3 countries, olanzapine: 1 country, risperidone: 4 countries, sumatriptan: 2 countries) (Figure 1).

Expressed in absolute figures, the prices per pack of generics were lower as of € 134.77 (Denmark) to € 0.85 (Belgium) for gemcitabine (no price difference in France, Greece and Norway); of € 190.73 (Switzerland) to € 1.72 (Norway) for mycophenolate mofetil (no difference in Austria, Belgium and Spain); of € 77.49 (Finland) to € 0.04 (Spain) for olanzapine (no difference in Norway); of € 95.35 (United Kingdom) to € 0.82 (Italy) for risperidone (no difference in Belgium, Ireland, Norway and Spain); and of € 45.04 (Belgium) to € 0.39 (Greece) for sumatriptan (no difference in Norway and Spain).

Since the unit prices for the medicines analyzed were, apart for gemcitabine, usually less than four Euro, the unit price differences in Euro were accordingly low. Figure 2 explored the possible relationship between the extent of the price differences and generic price. Some limited pattern is visible in a few countries: for instance, Norway and, to some extent also Ireland, tended to have comparably higher prices and low or even no price differences between the originator and the generic. At the other end, Sweden, Finland and Denmark ranked low regarding generic prices of the studied medicines but had, as a trend, differences of more than 70%, and sometimes 90%, between the originator and the generic prices. A similar picture was seen in the United Kingdom and the Netherlands, however in a less consistent way than in the three Nordic countries.

No correlation was found between the extent of the price difference and the relevance of the generics market, expressed in the outpatient generics market share in volume (Figure 3). While countries with an advanced generics market such as Finland and Sweden displayed in some cases higher price differences, this is not the case for Germany and Norway. On the other hand, Portugal, with a rather lower generics market share, displayed price differences of some relevance.

Table II provides an overview of the "classical" policy measures with regard to generic promotion for the countries analyzed which were clustered into ones with apparently high and low price differences. All three countries with high price differences (Denmark, Sweden and Finland) did not link the prices of generics to the ones of originators, while the countries identified to have low or no price differences (Belgium, Greece, Norway, Spain) did so. Countries with high price differences tended to have generic substitution introduced on a mandatory basis.

Figure 1. Price differences (expressed as the percentage which the price of the generic is lower than the one of the originator) between identical presentations of the originator and generic for five molecules in 16 European countries, data as of November 2011

AT = Austria; BE = Belgium; CH = Switzerland; DE = Germany; DK = Denmark; EL = Greece; ES = Spain; FI = Finland; FR = France; IE = Ireland; IT = Italy; NL = the Netherlands; NO = Norway; PT = Portugal; SE = Sweden; UK = United Kingdom
Information about generic policies and the generics market was provided by PPRI (Pharmaceutical Pricing and Reimbursement Information) network members. PPRI is a networking and information-sharing initiative on pharmaceutical policies from a public health perspective which emerged from a European Commission co-funded project under the same name [28,29]. As in June 2012, PPRI consisted of nearly 70 institutions, mainly Medicines Agencies, Ministries of Health and Social Insurance institutions, from 40 countries, including all 27 EU Member States, plus European and international institutions (European Commission services and agencies, OECD, WHO and World Bank). PPRI network members provide on a regular basis information and data about pharmaceutical policy measures and outcome indicators to the PPRI secretariat which collects and manages these data in the so-called PHIS (Pharmaceutical Health Information System) database [30]. Though the indicators are published in an annually updated version in the Internet, for this manuscript the internal version of the PHIS database was consulted in order to obtain, wherever possible, information and data as of November 2011. While the quality as well as coverage of data on policy measures are accurate due to regular contact and requests to the PPRI members, the data quality regarding the generics market shares is limited since authorities in some countries do not have exact and up-to-date data. The author therefore validated these data by consulting published data from the European Generics Association (EGA) which refer to the market shares as of 2006 [31]. Apart from Finland (low generics market share in the EGA data) no major inconsistency was detected.

RESULTS

The price differences between the originator and the equivalent generic medicine of the five selected molecules varied among the fifteen countries: from 1.4% (Belgium) to 73.4% (Portugal) for gemicitabine (comparable data available for 12 countries), from 3.4% (Norway) to 71.7% (the Netherlands) for mycophenolate mofetil (16 countries), from 0.1% (Spain) to 97.1% (Sweden) for olanzapine (13 countries), 0.9% (the Netherlands) to 97.3% (UK) for risperidone (16 countries) and from 5.8% (Greece) to 95.0% (Denmark) for sumatriptan (11 countries).

Additionally, for all five molecules analyzed there was at least one country where the price of the generic was identical to the one of the original product (gemicitabine: 3 countries, mycophenolate mofetil: 3 countries, olanzapine: 1 country, risperidone: 4 countries, sumatriptan: 2 countries) (Figure 1).

Expressed in absolute figures, the prices per pack of generics were lower as of € 134.77 (Denmark) to € 0.85 (Belgium) for gemicitabine (no price difference in France, Greece and Norway); of € 190.73 (Switzerland) to € 1.72 (Norway) for mycophenolate mofetil (no difference in Austria, Belgium and Spain); of € 77.49 (Finland) to € 0.04 (Spain) for olanzapine (no difference in Norway); of € 95.35 (United Kingdom) to € 0.82 (Italy) for risperidone (no difference in Belgium, Ireland, Norway and Spain); and of € 45.04 (Belgium) to € 0.39 (Greece) for sumatriptan (no difference in Norway and Spain).

Since the unit prices for the medicines analyzed were, apart for gemicitabine, usually less than four Euro, the unit price differences in Euro were accordingly low. Figure 2 explored the possible relationship between the extent of the price differences and generic price. Some limited pattern is visible in a few countries: for instance, Norway and, to some extent also Ireland, tended to have comparatively higher prices and low or even no price differences between the originator and the generic. At the other end, Sweden, Finland and Denmark ranked low regarding generic prices of the studied medicines but had, as a trend, differences of more than 70%, and sometimes 90%, between the originator and the generic prices. A similar picture was seen in the United Kingdom and the Netherlands, however in a less consistent way than in the three Nordic countries.

No correlation was found between the extent of the price difference and the relevance of the generics market, expressed in the outpatient generics market share in volume (Figure 3). While countries with an advanced generics market such as Finland and Sweden displayed in some cases higher price differences, this is not the case for Germany and Norway. On the other hand, Portugal, with a rather lower generics market share, displayed price differences of some relevance.

Table II provides an overview of the “classical” policy measures with regard to generic promotion for the countries analyzed which were clustered into ones with apparently high and low price differences. All three countries with high price differences (Denmark, Sweden and Finland) did not link the prices of generics to the ones of originators, while the countries identified to have low or no price differences (Belgium, Greece, Norway, Spain) did so. Countries with high price differences tended to have generic substitution introduced on a mandatory basis.
How large are the differences between originator and generic prices? Analysis of five molecules in 16 European countries

Figure 2. Price differences (expressed as the percentage which the price of the generic is lower than the one of the originator) between identical presentations of the originator and generic and the prices of the generic medicine per unit for five molecules in 16 European countries, data as of November 2011.

AT = Austria; BE = Belgium; CH = Switzerland; DE = Germany; DK = Denmark; EL = Greece; ES = Spain; FI = Finland; FR = France; IE = Ireland; IT = Italy; NL = the Netherlands; NO = Norway; PT = Portugal; SE = Sweden; UK = United Kingdom.

---

Gemcitabine, 1 vial 1 g powder for solution for infusion (n = 12)
No price comparison possible in DE, ES, IE, SE due to missing generics in a comparable presentation

Mycophenolate mofetil, 100 caps 250 mg (n = 16)
AT: different pack size and dosage (150 500 mg/caps), BE, CH, DK: 300 units, but same dosage and pharmaceutical form

Olanzapine, 28 f/c tabs 10 mg (n = 13)
NL: data adjusted at unit level - 30 units/pack for original product, 26 units/pack for generic; NO: different pharmaceutical form: immediate-release tabs; SE: 56 units, same dosage and pharmaceutical form

Risperidone, 60 f/c tabs 4 mg (n = 16)

Sumatriptan, 6 f/c tabs 50 g (n = 11)
ES and EL: 4 units; PT: 2 units, same pack size and pharmaceutical form; BE: 100 mg f/c tabs
Figure 2. Price differences (expressed as the percentage which the price of the generic is lower than the one of the originator) between identical presentations of the originator and generic and the prices of the generic medicine per unit for five molecules in 16 European countries, data as of November 2011.

AT = Austria; BE = Belgium; CH = Switzerland; DE = Germany; DK = Denmark; EL = Greece; ES = Spain; FI = Finland; FR = France; IE = Ireland; IT = Italy; NL = the Netherlands; NO = Norway; PT = Portugal; SE = Sweden; UK = United Kingdom.

Figure 3. Price difference (expressed as the percentage which the price of the generic is lower than the one of the originator, price data as of November 2011) between identical presentations of the originator and generic for five molecules and generics market shares* in 16 European countries.

* generics market share in volume in the out-patient sector. No data available for CH, EL, IE. Note on generics market shares: 2004 = IT; 2005 = DE; 2006 = SE; 2007 = AT; 2008 = FI; 2010 = BE; out-patient reimbursed sector = ES; AT = Austria; BE = Belgium; CH = Switzerland; DE = Germany; DK = Denmark; EL = Greece; ES = Spain; FI = Finland; FR = France; IE = Ireland; IT = Italy; NL = the Netherlands; NO = Norway; PT = Portugal; SE = Sweden; UK = United Kingdom.
How large are the differences between originator and generic prices? Analysis of five molecules in 16 European countries

DISCUSSION

Despite of the limitation of a rather small basket of molecules analyzed, some pattern among the studied countries can be observed. Some countries had consistently no or little price differences between the originator and the generic product, while others displayed price differences ranging from 50 to up to nearly 100 percent for the molecules analyzed: Belgium, Greece, Norway and Spain ranked at the lower end for most of the molecules analyzed. There appears to be a need for improved generic promotion in Belgium, Greece and Spain since generics market shares are rather low (Figure 3). While policy measures to promote generics uptake are in place in these countries (Table II), they have apparently not been fully exploited: for instance, generic substitution and/or INN promotion have been implemented on an indicative basis and not in a mandatory way, and the percentage rate defined in the generic price link policy appears comparably low. In Belgium, while the reference price system has stimulated the generics market and has led to a reduction of the originator prices as well, the possible role of prescribers and pharmacists in enhancing generics uptake were not sufficiently considered [32]. In Spain, generic policies are seen as an important policy option, and the country introduced some changes with the summer 2011 reform package which included speeding up of the establishment of reference groups in the reference price system, a change in the methodology in generic substitution allowing a broader use and making INN prescribing mandatory [33]. Greece has been criticized for long – not only for the missing implementation of a consistent generic promotion policy but also, in general, for the lack of a sustainable health care and pharmaceutical policy [34-36].

It is a rather surprising result that Norway showed no price difference for four of the five molecules and only a minor one for the fifth. This also contradicted evidence about the country’s low generic prices resulting from its active generic policies. Norway has been promoting generics primarily via the “stepped price model” (Trinnprismodellen) which provides incremental price decreases according to pre-defined rates, depending on sales volu-

<table>
<thead>
<tr>
<th>Country</th>
<th>Generic price link</th>
<th>Reference price system</th>
<th>Generic substitution</th>
<th>INN prescribing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Countries with high price differences between originator and generic</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Denmark</td>
<td>No</td>
<td>RPS at ATC 5</td>
<td>Yes, mandatory</td>
<td>Yes, indicative</td>
</tr>
<tr>
<td>Finland</td>
<td>No</td>
<td>RPS at ATC 5</td>
<td>Yes, mandatory</td>
<td>Yes, indicative</td>
</tr>
<tr>
<td>Sweden</td>
<td>No</td>
<td>No</td>
<td>Yes, mandatory</td>
<td>Not allowed</td>
</tr>
<tr>
<td>Countries with moderate price differences between originator and generic and/or no clear picture for the studied molecules</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Austria</td>
<td>Yes</td>
<td>No</td>
<td>Not allowed</td>
<td>Not allowed</td>
</tr>
<tr>
<td>Germany</td>
<td>No</td>
<td>RPS with broad clusters</td>
<td>Yes, mandatory</td>
<td>Yes, indicative</td>
</tr>
<tr>
<td>France</td>
<td>Yes</td>
<td>RPS at ATC 5</td>
<td>Yes, indicative</td>
<td>Yes, indicative</td>
</tr>
<tr>
<td>Ireland</td>
<td>Yes</td>
<td>No</td>
<td>Not allowed</td>
<td>Yes, indicative</td>
</tr>
<tr>
<td>Italy</td>
<td>Yes</td>
<td>RPS at ATC 5</td>
<td>Yes, indicative</td>
<td>Yes, indicative</td>
</tr>
<tr>
<td>Netherlands</td>
<td>No</td>
<td>RPS with broad clusters</td>
<td>Yes, indicative</td>
<td>Yes, indicative</td>
</tr>
<tr>
<td>Portugal</td>
<td>Yes</td>
<td>RPS at ATC 5</td>
<td>Yes, indicative</td>
<td>Yes, mandatory</td>
</tr>
<tr>
<td>Switzerland</td>
<td>N.a.</td>
<td>No</td>
<td>Yes, indicative</td>
<td>No</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>No</td>
<td>No</td>
<td>Not allowed</td>
<td>Yes, indicative and highly encouraged</td>
</tr>
<tr>
<td>Countries with low price differences between originator and generic</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Belgium</td>
<td>Yes</td>
<td>RPS at ATC 5</td>
<td>Not allowed*</td>
<td>Yes, indicative</td>
</tr>
<tr>
<td>Greece</td>
<td>Yes</td>
<td>PRS at ATC 5</td>
<td>Not allowed</td>
<td>Yes, indicative</td>
</tr>
<tr>
<td>Norway</td>
<td>Yes</td>
<td>RPS at ATC 5</td>
<td>Yes, indicative</td>
<td>Yes, indicative</td>
</tr>
<tr>
<td>Spain</td>
<td>Yes</td>
<td>RPS at ATC 5</td>
<td>Yes, indicative</td>
<td>Yes, mandatory</td>
</tr>
</tbody>
</table>

Table II. Generic policy measures in the countries analyzed, clustered with regard to their extent of differences between originator and generic prices, as in November 2011

* Not allowed at the time to which the prices refer to (November 2011). Since 1 April 2012, every prescription of an antibiotic or antifungal medicine is regarded as a prescription by INN and the pharmacist is obliged to dispense the lowest priced medicine

ATC = Anatomic Therapeutic Chemical classification system by WHO; ATC 5 = defines a single active ingredient or a fixed combination of active ingredients within the ATC classification system, i.e. RPS is based on the same active ingredients; INN = International Non-Proprietary Name; RPS = Reference Price System
mes. The first reduction occurs after a medici-
ne has lost patent protection [37]. The “step-
preded price model” was considered accountable
for increasing the generics market shares and
lowering generic prices [37,38]. The hypo-
thesis that the non-existing or low price dif-
ferences might be a result from already existing
low generic prices, as a study about the ove-
rall market suggests [21], could not be con-
firmed for the molecules of this analysis: the
prices of the selected generics usually ranked
in the upper field (Figure 2). While further re-
search on this issue is, in general, encouraged,
it would be particularly of interest to study in
further depth generics prices in Norway.
The other Nordic states Sweden, Denmark
and also Finland were among those countries
showing the highest price differences betwe-
en the originator and an equivalent presen-
tation of the generic medicine. Generic mar-
kets in these countries are advanced (Figure
3), and generic policies are predominantly
based on competition. Denmark is one of
the few European countries which applies
tendering procedures in the out-patient sec-
tor: every two weeks, the reference product
(i.e. the one reimbursed) under the referen-
ce price system is tendered for, and only the
“winner” will be reimbursed [6,39]. While
the high frequency of the change certainly
implies logistical challenges, in particular
for pharmacies – and initial problems indeed
occurred leading to shortages resulting in the
National Health Service having to pay for
higher priced available medicines [6] –, the
tendering system creates a highly competi-
tive market environment. As one of the first
European countries Sweden implemented a
reference price system in 1993 but abolished
it in 2002. Nonetheless, within the system for
generic substitution substitutable medicines
are grouped together, and a price which is
lower or the same as the highest price within
a group of substitutable medicine is accep-
ted without further investigation. This po-
licy measure is supplemented by mandatory
generic substitution. Experts from Sweden
attribute savings in pharmaceutical expen-
diture to their generic policies, especially to
the mandatory generic substitution [10]. A
lesson learned from the Swedish action could
be that policy measures should not just be
implemented somehow but they need to be
enforced. Enforcement appears to be parti-
cularly relevant for generic substitution and
INN prescribing since countries having in-
troduced these measures in a mandatory way
tend to have higher generics uptake than tho-
se with indicative generic substitution and/or
INN prescribing [15]. While INN prescribing
and/or generic substitution is still implemen-
ted in an indicative way in most European
countries (see Table II), in recent times some
countries decided on a policy change by mak-
ing INN prescribing mandatory, generally
or at least for some products (e.g. Lithuania
in June 2010, Spain in August 2011, Slovakia
in December 2011 and recently Hungary for
statins in April 2012). Finland introduced a
reference price system in 2009 – this was at
a time when many other European countries
already had one. Even before the implementa-
tion of the reference price system, Finland
had an advanced generics market and could
generate savings from generics. This was at-
tributable to generic substitution which trig-
gerred price competition [40]. The reference
price system further enhanced generic com-
petition and drove prices down [41].
The picture on the Netherlands and the UK is
far less clear because high price differences
were displayed for some molecules whereas
the differences were moderate and even low
for others (Figure 1). Both the Netherlands
and the UK have a strong generics market
(Figure 3), and they have been promoting
generics for a long time though they chose
different approaches. The Netherlands intro-
duced a reference price system in the early
1990s and an electronic system to convert
brand prescriptions into INN prescriptions
and awarded for years (till 2004) a financial
incentive to pharmacists in return for generic
substitution [6,7,10,42]. During the last years
the so-called preference price policy for se-
lected molecules has been applied. The Dutch
price policy is, like in Denmark, a
tendering procedure in the out-patient sector
[43]. With this policy health insurance com-
panies determine one or a limited number of
medicine(s) per cluster (medicines with
the same active ingredient, dosage form and
strength) as preferred, each time for a fixed
period of usually six months. The preferred
medicine winning the tender will be reimbur-
sed [44]. In terms of savings the preference
price policy was considered as very suc-
cessful; initial total savings (projected to €
355 million annually) exceeded expectations
since the preference policy scheme resulted
in fierce price competition among generic
companies [45]. From the molecules studied
in this analysis, olanzapine, risperidone and
sumatriptan typically fall under the preferen-
ce price policy [46]. For these products, the
differences between originator and generic
prices are often quite low, and generic prices
are also at a low level (Figure 2). Apparently
price competition involved not only the ge-
nerics under the preference price system but
also the originator, and data suggest confirm-
ing analyses which highlight considerable

S. Vogler

Farmeconomia. Health economics and therapeutic pathways 2012; 13(Suppl 3) © SEEd All rights reserved

37
price reductions for the molecules under the preference price policy [47].

The UK contributes its high generics market shares to INN prescribing which is not mandatory but highly encouraged. It has neither a reference price system nor generic substitution; the government decided against the introduction of generic substitution planned for 2010 following a public consultation [15]. For the five molecules studied, high price differences (more than 90%) were identified in case of only two molecules, and for those the generic prices were low as well. For the other molecules analyzed, however, the differences were moderate and even low, and generic prices ranked in the middle and upper field (Figure 2). Studies criticized that the British National Health Service paid too high generic prices in the UK [48,49].

The situation appears similar for Germany for which results are only available for three molecules: Germany is known for a strong competitive generics market, based on a reference price system which provides broad reference groups in which even original products may be clustered as alternatives [6], and it has an advanced generics market (Figure 3). But the extent of the price differences was rather low, and generic prices were in the middle and upper field. This is in line with other price comparisons in Europe which showed rather high generic prices [20,21] and high originator prices in Germany [21]. Given the broad use of external price referencing in the nearly all other European countries, pharmaceutical industry was incentivized to first launch a medicine in Germany because, till recently, the country had a free pricing policy [50]. Having said that about Germany’s high price level, it should be reminded that the prices of medicines which are reimbursed by sickness funds are in fact lower due to discount agreements with the sickness funds [51-53].

Last but not least, Portugal deserves some discussion. Portugal has been working for more than a decade on promoting its generics market [6,54,55], but it has not always achieved the results envisaged. Till 2010, the generics market share in value used to be higher than the one in volume [56] which is an indication of excess generic prices. For years Portugal had defined the reference price equivalent to the highest priced generic in the reference group [15]. In 2010 policy makers decided to reset the price to the average of the five lowest priced medicines, and, also in response to the global financial crisis, strengthened its efforts on enforcing generics policies [16]. As the results illustrate, with regard to the price differences Portugal ranks middle (in the one case of gemcitabine it even displays the highest price difference amounting to more than 70%), and generic prices of the selected molecules are in the lower and middle field among the sixteen countries analyzed.

Whereas the discussion of the results at a country per country basis allows lessons to be learned about successful and less successful approaches in enhancing generics uptake, no correlations could be found at an overall level: It could neither be proven that countries with high price differences had consistently low generic prices nor that high price differences were a feature of advanced generic markets. This corresponds to results of a study investigating the relationship between generics market shares and the change of generic prices over time: It identified different extents of price decreases in the low and high generics market share countries [57].

While price data from the PPI service are considered as of good quality, and the information on policy measures is up-dated and should be as complete as possible, limitations regarding the generics market share do exist. Though based on a common definition, data on generics market shares were provided by country representatives from competent authorities and not by the market players, and they might include some inconsistencies with regard to the definition. Additionally, some generics market share data do not refer to 2009 but to previous years. The author considered taking the generics market shares provided by the European Generics Association, but decided against it since published information dates back to the year 2006.

The extent of the price differences might also be impacted by the different time periods which had passed since patent expiry. However, since the author had no access to the exact patent expiry dates of the molecules of the study, such analysis could not be performed. Another limitation is the rather small sample of products. The limited size of the sample is also due to the fact that it was hard to identify identical – or at least comparable – presentations of the originator and the generic product in a reasonable number of countries. The author initially checked a sample of a total of 22 medicines with a generic alternative in at least one country derived from the PPI service. For the reasons described in the methodology section only five molecules were eligible for the analysis. With the on-going expiry of patents the analysis might be repeated in future with a broader product sample.

CONCLUSIONS

Even if this research is illustrative and not representative due to the small sample, the
ACKNOWLEDGEMENTS

I would like to deeply thank my colleagues from the Austrian Health Institute who work for the PPI (Pharmaceutical Price Information) service for providing the price data used in this analysis. In particular, I would like to convey my thanks to Claudia Habl, Florian Bachner and Bettina Schmickl for their extensive work on the price data compilation which was a valuable asset and prerequisite for doing the analysis. I am grateful to Escra Coskun, Ingrid Freiberger, Patricia de Groot, Joy Ladurner, Christine Leopold, Klaus Kellner, Judith Oberdammer, Daniela Pertl, Günter Sprinzl and Nina Zimmermann; together with Claudia Habl, Florian Bachner and Bettina Schmickl they did an excellent job to collect price data in the 16 countries. Furthermore, I highly appreciate the commitment and activities of the members of PPRI (Pharmaceutical Pricing and Reimbursement Information) network. For this paper, I could draw from their regularly provided information about the pharmaceutical policy measures and the generics market shares. Finally, I thank my colleague Nina Zimmermann for the maintenance of the PHIS database and the regular updates.

REFERENCES


How large are the differences between originator and generic prices? Analysis of five molecules in 16 European countries


18. Danzon PM, Chao LW. Cross-national price differences for pharmaceuticals: how large, and why? *J Health Econ* 2000; 19: 159-95


43. Dylst P, Vulto A, Simoens S. Tendering for outpatient prescription pharmaceuticals: What can be learned from current practices in Europe? *Health Policy* 2011; 101: 146-52; [http://dx.doi.org/10.1016/j.healthpol.2011.03.004](http://dx.doi.org/10.1016/j.healthpol.2011.03.004)

44. Zuidberg C. The pharmaceutical system of the Netherlands. A comparative analysis between the Dutch out-patient pharmaceutical system, in particular the pricing and reimbursement characteristics, and those of the other European Union Member States, with a special focus on tendering-like systems. Vienna: Gesundheit Österreich GmbH, 2010


